Full-Time
Posted on 1/22/2025
Molecular diagnostics for prenatal and oncology testing
$51kAnnually
Junior, Mid
Remote in USA
You match the following BillionToOne's candidate preferences
Employers are more likely to interview you if you match these preferences:
BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases by identifying minute variations in DNA at a single base-pair level. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to enhance the precision and efficiency of molecular testing, ultimately making a positive impact on healthcare.
Company Size
201-500
Company Stage
Series D
Total Funding
$380.2M
Headquarters
Menlo Park, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne
2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu
MENLO PARK, Calif., Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2025.BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years.This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows:Location: Mission Bay (32nd Floor) at The WestinDate: Tuesday, January 14, 2025Time: 2:30-2:55 pm PTA webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards.
Molecular diagnostics firm BillionToOne broke ground Wednesday on a 220,000-sq-ft facility in Austin, TX, that is expected to bring 1,000 jobs to the city.
BillionToOne, which is headquartered in California, is set to build a new facility in Austin's EastVillage.
VICTORIA, BC, Sept. 4, 2024 /PRNewswire/ - Semaphore Solutions, a leader in laboratory informatics solutions, is pleased to announce the expansion of its partnership with next-generation molecular diagnostics company, BillionToOne.
Lectură de 4 minÎn 2013, când a început să fie folosit termenul de ”unicorn” pentru startup-urile tech evaluate la peste 1 miliard de dolari, în lume existau 39 de unicorni. Anul trecut, datele numărau cu puțin peste 1.200 de unicorni, cu o valoare cumulată estimată la 3.856 miliarde de dolari. Anul acesta, în plan global au apărut 38 de unicorni în lumea startup-urilor. Care sunt acele companii care ne-au atras atenția?Înainte de a trece la cei mai noi unicorni ai lumii și la inovația pe care o aduc, reluăm definiția unicornului din punct de vedere al unui startup, așa cum a apărut el în mod original.Un unicorn este un startup de tehnologie privat care a ajuns să fie evaluat la cel puțin un miliard de dolari. Astfel, compania este în fază de dezvoltare și are și particularitate aunui startup, aceea de scalabilitate și a faptului că folosește tehnologia sau aduce un element inovator pentru a avea impact în viețile oamenilor. Ca să se încadreze la ”unicorn”, compania trebuie să fie privată, adică să nu aibă acțiuni la bursă, disponibile publicului larg.În schimb, acțiunile companiei sunt oferite anumitor persoane, ori sunt tranzacționate sau schimbate în mod privat, investitorii fiind cei care setează și bazele evaluării în funcție de sumele pe care aleg să le aloce acelui startup
ACOG supports cfDNA testing as a reasonable alternative for fetal RBC testing among alloimmunized patientsMENLO PARK, Calif., July 26, 2024 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is thrilled to announce a new publication that shows cfDNA analysis is highly sensitive and specific for determining fetal antigen genotype as early as 10 weeks gestation. The new study published online in Obstetrics and Gynecology, the official journal of the American College of Obstetricians and Gynecologists (ACOG), also known as "The Green Journal," supports the implementation of cfDNA testing to manage alloimmunized pregnancies in the United States. This study follows the recent ACOG clinical practice update that supports cfDNA testing as a reasonable alternative to amniocentesis for fetal RBC testing among alloimmunized patients.Hemolytic disease of the fetus or newborn (HDFN) is a potentially life-threatening form of anemia caused by alloimmunization. ACOG recommends testing the reproductive partner's antigen status when alloimmunization is diagnosed in pregnancy. However, rates of reproductive partner screening uptake are low, and results can be misleading in the setting of nonpaternity.In September 2022, BillionToOne's UNITY Fetal Antigen NIPT became the first commercially available cfDNA test in the US, providing highly accurate assessments of the fetal status for RhD, c, C, E, K and Fya antigens. It is the only clinically available NIPT in the US that includes antigens beyond RhD and is offered as an add on to UNITY Complete , the first and only test that uses cell-free DNA to provide precise fetal insights for both recessive and chromosomal conditions.The Green Journal study demonstrates the accuracy of an NGS-based cfDNA analysis assay using BillionToOne's proprietary Quantitative Counting Templates™ (QCT™) for the detection of fetal red blood cell antigen status in a large, diverse U.S.-based cohort
Diagnostic developer BillionToOne has clocked a billion-dollar valuation, after raising $130 million in venture capital funding. | BillionToOne said the proceeds will help scale up its blood testing businesses in prenatal screening and cancer.
Sid's Farm has raised $10 million in a Series A round of funding, while PremjiInvest has led a $130-million Series D funding round in US-based BillionToOne.